Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC O ANDERSON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1154307197
CMS profile
323983
Location
LAYTON, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$768.13

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $768.13 55

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC O ANDERSON

NPI 1154307197 · CMS profile ID 323983

Allopathic & Osteopathic Physicians / Family Medicine

LAYTON, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154307197?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC O ANDERSON, NPI 1154307197, CMS profile ID 323983. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154307197?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MARC O ANDERSON, NPI 1154307197, CMS profile ID 323983. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154307197?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MARC O ANDERSON, NPI 1154307197, CMS profile ID 323983, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1154307197?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $768.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $18.4101/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720477283 CMS
GlaxoSmithKline, LLC. $17.3301/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738618679 CMS
GlaxoSmithKline, LLC. $15.5201/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738641509 CMS
PFIZER INC. $12.7301/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743664197 CMS
SANOFI-AVENTIS U.S. LLC $12.8701/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744093169 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,147.28 93
PY2020 $768.13 55
PY2021 $1,008.00 80
PY2022 $1,017.94 64
PY2023 $2,525.39 60
PY2024 $913.23 46
PY2025 $252.80 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $607,712.85 60
PY2024 Principal investigator $437,409.98 31
PY2023 Principal investigator $823,472.54 83
PY2022 Principal investigator $644,706.74 53
PY2021 Principal investigator $180,248.51 14
PY2020 Principal investigator $63,323.50 7
PY2019 Principal investigator $61,840.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $720.00 12/17/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955339
Principal investigator 1 ModernaTX, Inc. $360.00 12/05/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955371
Principal investigator 1 ModernaTX, Inc. $27,035.90 12/03/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955295
Principal investigator 1 ModernaTX, Inc. $6,610.55 12/03/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955315
Principal investigator 1 ModernaTX, Inc. $6,696.00 12/01/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955309
Principal investigator 1 ModernaTX, Inc. $3,000.00 12/01/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955359
Principal investigator 1 ModernaTX, Inc. $360.00 12/01/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955379
Principal investigator 1 ModernaTX, Inc. $50,866.11 11/14/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955355
Principal investigator 1 ModernaTX, Inc. $310.03 11/12/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955277
Principal investigator 1 ModernaTX, Inc. $353.47 11/12/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955287
Principal investigator 1 ModernaTX, Inc. $330.81 11/07/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955265
Principal investigator 1 ModernaTX, Inc. $3,600.00 11/07/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955293
Principal investigator 1 ModernaTX, Inc. $35.00 11/07/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955317
Principal investigator 1 ModernaTX, Inc. $500.00 11/03/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955321
Principal investigator 1 ModernaTX, Inc. $1,800.00 10/29/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955361
Principal investigator 1 ModernaTX, Inc. $12,144.84 10/24/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955305
Principal investigator 1 ModernaTX, Inc. $351.62 10/24/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955351
Principal investigator 1 ModernaTX, Inc. $1,200.00 09/24/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955345
Principal investigator 1 ModernaTX, Inc. $7,306.68 09/19/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955279
Principal investigator 1 ModernaTX, Inc. $14,845.96 09/12/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955297
Principal investigator 1 ModernaTX, Inc. $13,243.24 09/12/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955323
Principal investigator 1 ModernaTX, Inc. $12,948.00 08/27/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955377
Principal investigator 1 ModernaTX, Inc. $8,865.80 08/20/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955349
Principal investigator 1 ModernaTX, Inc. $6,154.80 07/23/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955273
Principal investigator 1 ModernaTX, Inc. $18,500.20 07/23/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955275
Principal investigator 1 ModernaTX, Inc. $25,324.38 07/23/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955291
Principal investigator 1 ModernaTX, Inc. $9,261.00 07/23/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955307
Principal investigator 1 ModernaTX, Inc. $17,211.02 06/25/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955311
Principal investigator 1 ModernaTX, Inc. $3,584.00 06/18/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955271
Principal investigator 1 ModernaTX, Inc. $7,344.00 06/18/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955281
Principal investigator 1 ModernaTX, Inc. $49,228.80 06/18/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955347
Principal investigator 1 ModernaTX, Inc. $500.00 06/02/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955267
Principal investigator 1 ModernaTX, Inc. $1,200.00 06/02/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955269
Principal investigator 1 ModernaTX, Inc. $7,400.00 06/02/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955313
Principal investigator 1 ModernaTX, Inc. $25,920.70 06/02/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955353
Principal investigator 1 ModernaTX, Inc. $1,400.00 06/02/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955357
Principal investigator 1 ModernaTX, Inc. $31,174.20 05/28/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955289
Principal investigator 1 ModernaTX, Inc. $33,787.68 05/23/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955327
Principal investigator 1 ModernaTX, Inc. $360.00 05/23/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955381
Principal investigator 1 ModernaTX, Inc. $20,820.00 05/21/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955373
Principal investigator 1 ModernaTX, Inc. $91,994.94 05/07/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955319
Principal investigator 1 ModernaTX, Inc. $11,047.32 04/18/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955341
Principal investigator 1 ModernaTX, Inc. $360.00 04/09/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955367
Principal investigator 1 ModernaTX, Inc. $720.00 04/09/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955369
Principal investigator 1 ModernaTX, Inc. $350.00 04/09/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955383
Principal investigator 1 ModernaTX, Inc. $4,600.00 04/04/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955325
Principal investigator 1 ModernaTX, Inc. $4,300.00 04/04/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955333
Principal investigator 1 ModernaTX, Inc. $2,700.00 04/04/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955335
Principal investigator 1 ModernaTX, Inc. $14.80 04/01/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955375
Principal investigator 1 ModernaTX, Inc. $150.00 03/21/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955299
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/21/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955331
Principal investigator 1 ModernaTX, Inc. $5,600.00 03/21/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955365
Principal investigator 1 ModernaTX, Inc. $6,831.00 03/19/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955283
Principal investigator 1 ModernaTX, Inc. $2,850.00 03/14/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955363
Principal investigator 1 ModernaTX, Inc. $4,200.00 03/12/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955301
Principal investigator 1 ModernaTX, Inc. $600.00 03/12/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955303
Principal investigator 1 ModernaTX, Inc. $396.00 03/12/2025 Non-covered Recipient Entity
TANNER CLINIC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955329
Principal investigator 1 ModernaTX, Inc. $18,705.00 02/26/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955343
Principal investigator 1 ModernaTX, Inc. $360.00 02/05/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955285
Principal investigator 1 ModernaTX, Inc. $18,279.00 01/29/2025 Non-covered Recipient Entity
TANNER CLINIC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252955337